WADA’s 2013 alert states that GW501516 development was terminated after serious preclinical toxicities. The alert supports a significant development-stage safety concern, but not a numerical human cancer risk.[2]
- Original animal toxicology tables were not inspected; no species-specific tumor incidence or causal human cancer claim is made.
- The alert's own one-page text does not use the words cancer, tumor or carcinogenicity and cites no specific study, species or dose; it is an anti-doping notice reporting a pharmaceutical company's development decision, not a published toxicology report.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Reopened the original one-page WADA/FIA alert PDF directly (HTTP 200) and read it in full in both languages; reconfirmed the claim's quoted language verbatim (development terminated when serious toxicities were discovered in pre-clinical studies) and confirmed the alert itself never uses the words cancer, tumor or carcinogenicity and names no specific study, species, dose or organ. A further PubMed search for the underlying rodent carcinogenicity bioassay (queries: GW501516 carcinogenicity rat, GW501516 tumorigenicity, GW501516 rodent bioassay, endurobol toxicology) found no dedicated peer-reviewed publication of that bioassay; results returned only general PPAR-delta cancer-biology mechanistic papers unrelated to this specific compound's preclinical program. This remains an explicit, unresolved evidence gap, not a finding either way about carcinogenic risk. Independent editorial review pending.